论文部分内容阅读
目的观察柳氮磺吡啶联合双歧杆菌三联活菌胶囊治疗溃疡性结肠炎患者的临床疗效及对细胞因子的影响。方法 92例溃疡性结肠炎患者随机分为观察组47例、对照组45例。观察组给予柳氮磺吡啶肠溶片1.0 g,每日4次,双歧杆菌三联活菌胶囊0.63 g,每日3次。对照组给予柳氮磺吡啶1.0 g,每日4次,均为餐后服用,总疗程为8 wk,观察2组治疗前后的临床综合疗效及细胞因子白细胞介素6(IL-6)、白细胞介素8(IL-8)、肿瘤坏死因子α(TNF-α)的变化。结果观察组的临床综合疗效优于对照组(P<0.05),2组血清TNF-α、IL-6、IL-8含量均下降,观察组与治疗前比较有明显差异(P<0.01),观察组的改变明显优于对照组(P<0.01)。结论柳氮磺吡啶联合双歧杆菌三联活菌胶囊治疗溃疡性结肠炎能恢复机体免疫调控功能,提高临床疗效。
Objective To observe the clinical efficacy of sulfasalazine combined with Bifidobacterium triple viable capsule in patients with ulcerative colitis and its effect on cytokines. Methods A total of 92 patients with ulcerative colitis were randomly divided into observation group (n = 47) and control group (n = 45). Observation group was given sulfasalazine enteric-coated tablets 1.0 g, 4 times a day, Bifidobacterium triple viable capsules 0.63 g, 3 times a day. Control group was given sulfasalazine 1.0 g, 4 times a day, were taken after meal, the total course of treatment was 8 wk, observed two groups before and after treatment of clinical efficacy and cytokines interleukin 6 (IL-6), white blood cells Interleukin-8 (IL-8), tumor necrosis factor alpha (TNF-alpha) changes. Results The clinical efficacy of the observation group was better than that of the control group (P <0.05). The levels of serum TNF-α, IL-6 and IL-8 in the observation group were significantly lower than those in the control group The observation group changed significantly better than the control group (P <0.01). Conclusion Sulfasalazine combined with Bifidobacterium triple viable capsule in the treatment of ulcerative colitis can restore immune function and improve clinical efficacy.